Featured

Status

Health Topics

Any Category
Diseases
Hemic and Lymphatic Diseases
Clear Filters

Search Clinical Trials

64 Results
Active, Not Recruiting
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
Investigators will test a biopsy of the tumor to see if the tumor cells are EBV positive and to see if the subject is eligible for this study. Then they …
Baylor Role: Lead Sponsor
Withdrawn
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
OBJECTIVES: Primary - Determine the complete radiologic response rate in patients with primary CNS lymphoma treated with salvage chemotherapy comprising temozolomide and topotecan. Secondary - Determine the median and failure-free …
Baylor Role: Collaborator
Active, Not Recruiting
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
In order to transplant stem cells we will need to give the patient drugs or high-dose chemotherapy to kill or destroy most of the blood forming and immune cells in …
Baylor Role: Lead Sponsor
Terminated
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)
Investigators first tested a biopsy of the tumor that has already been done to see if the tumor cells are EBV positive. They then got permission to take up to …
Baylor Role: Lead Sponsor
Completed
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
ALASCER (Part 1 of 2) We will generate autologous (or syngeneic) or allogeneic LMP2A-specific cytotoxic T-cells and adoptively transfer them to patients with relapsed EBV-positive Hodgkin's or non-Hodgkins Lymphoma or …
Baylor Role: Lead Sponsor
Completed
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
This is a phase I trial to assess the safety of a dose escalation of hCD40L-expressing autologous tumor cells with a fixed dose of recombinant hIL-2 gene transduced autologous leukemic …
Baylor Role: Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role: Lead Sponsor
Completed
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
After subjects have completed the pretreatment evaluations, they will receive an injection of Enbrel - the study drug -(given under the skin) twice weekly. If the subjects disease stabilizes or …
Baylor Role: Lead Sponsor
Completed
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
Participation in this study will be for one year. Patients will receive this treatment either while in hospital or in the outpatient clinic. Each patient will be entered into one …
Baylor Role: Lead Sponsor
Completed
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
This is a two arm study in which outcomes will be assessed independently in recipients of HLA matched sibling transplants and recipients of unrelated or mismatched family donor transplants, although …
Baylor Role: Lead Sponsor